<DOC>
	<DOCNO>NCT00220727</DOCNO>
	<brief_summary>The objective study determine safety tolerability Immune Globulin Intravenous ( Human ) , 10 % Caprylate/Chromatograph Purified ( IGIV-C ) similar infuse two different infusion rate .</brief_summary>
	<brief_title>Rapid Infusion Of Immune Globulin Intravenous ( IGIV ) In Patients With ITP</brief_title>
	<detailed_description>This prospective , randomize , single-center , open , cross-over trial patient confirm diagnosis Idiopathic Thrombocytopenia Purpura ( ITP ) . ITP define isolated thrombocytopenia patient clinically apparent associate condition factor know cause thrombocytopenia define ITP Practice Guidelines Committee American Society Hematology . Immune Globulin Intravenous ( Human ) , 10 % Caprylate/Chromatography Purified ( IGIV-C ) dose 1.0 g/kg give 2 occasion single daily infusion platelet count &lt; 30,000 microliters ( uL ) clinically indicate , maximum interval six week . Eligible patient randomize one two cross-over group . Patients randomize Group 1 receive first IGIV-C infusion rate 0.08 mL/kg/min second infusion rate 0.14 mL/kg/min . Conversely patient randomize Group 2 receive first IGIV-C infusion rate 0.14 mL/kg/min second infusion rate 0.08 mL/kg/min accord follow schema : Group 1 : - Infusion # 1 ( Week 0 ) IGIV-C ( 0.08 mL/kg/min ) - Infusion # 2 ( Week &lt; 6 ) IGIV-C ( 0.14 mL/kg/min ) Group 2 : - Infusion # 1 ( Week 0 ) IGIV-C ( 0.14 mL/kg/min ) - Infusion # 2 ( Week &lt; 6 ) IGIV-C ( 0.08 mL/kg/min )</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Written inform consent patient legal guardian ( accord institutional review board requirement ) obtain prior initiation study relate procedure Male female subject age 12 75 year Confirmed diagnosis ITP log medical record available prior entry trial . Patients must platelet count &lt; 30 x Giga/L ( level higher clinically indicate ) . Previously splenectomized patient may include . Any previously conduct bone marrow aspiration conduct follow diagnosis ITP must consistent ITP diagnosis ( increase normal level megakaryocyte otherwise normal bone marrow ) . History allergic clinically significant reaction human gamma globulin plasma proteins and/or blood product . Female patient pregnant lactating adequate program contraception childbearing potential . Documented history selective immunoglobulin A ( IgA ) deficiency ( serum &lt; 5.0 mg/dL ) know antibody IgA . Currently intermittent prednisone therapy . Prednisone therapy allow patient stable daily dose prednisone precede month maintains treatment regimen throughout study . Renal liver impairment define creatinine &gt; 2.5 mg/dL , direct bilirubin &gt; 1.5 X upper limit normal liver transaminase ( AST ALT ) &gt; 3 time upper limit normal . Received antiD IGIV infusion within past 14 day Pretreatment exception acetominophen , routinely required control/ameliorate IGIV infusionrelated adverse event ( AEs ) , patient , unresponsive IGIV therapy ITP History clinical evidence medical condition felt underlying cause thrombocytopenia . Such condition commonly include systemic lupus erythematosus , history chronic lymphocytic leukemia , dysplasia , agammaglobulinemia , treatment heparin , quinidine , quinine , trimethoprimsulfamethoxazole , ticlopidine drug think cause patient 's thrombocytopenia , congenital hereditary thrombocytopenia , pseudothrombocytopenia ( clump peripheral blood smear ) Conditions could alter protein catabolism and/or immunoglobulin G ( IgG ) utilization ( e.g . proteinlosing enteropathy , nephrotic syndrome ) Congestive heart failure ( New York Heart Association Stage III IV ) Diabetes mellitus Paraproteinemia Concomitant nephrotoxic drug Hemoglobin level 2g/L low limit normal .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Idiopathic ( Immune ) Thrombocytopenic Purpura</keyword>
	<keyword>Immunoglobulin G</keyword>
</DOC>